Lexaria Bioscience
LEXX
22 hedge funds and large institutions have $2.12M invested in Lexaria Bioscience in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
1.2% less ownership
Funds ownership: 8.26% → 7.06% (-1.2%)
12% less funds holding
Funds holding: 25 → 22 (-3)
30% less capital invested
Capital invested by funds: $3.03M → $2.12M (-$907K)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$236K |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$221K |
| 3 |
BAM
Byrne Asset Management
Kingston,
New Jersey
|
+$27K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.8K |
| 5 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$3.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$966K |
| 2 |
Morgan Stanley
New York
|
-$42.5K |
| 3 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$21K |
| 4 |
RS
R Squared
Central,
Hong Kong
|
-$5.5K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3.39K |
LEXX Hedge Fund Activity: Q1 2025 in Review
22 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q1 2025, worth a combined $2.12M — down 30% from $3.03M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LEXX and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was Invenomic Capital Management, adding an estimated $236K. The largest seller was Armistice Capital, exiting entirely with an estimated $966K sold.
- 22 institutional investors held Lexaria Bioscience (LEXX) as of Q1 2025, down from 25 in Q4 2024.
- Funds reported $2.12M of Lexaria Bioscience stock for Q1 2025, down 30% quarter-over-quarter.
- 2 funds opened new Lexaria Bioscience positions in Q1 2025 and 5 closed out, a net change of -3 holders.
- The largest Lexaria Bioscience buyer in Q1 2025 was Invenomic Capital Management, an estimated $236K added.
- The largest Lexaria Bioscience seller in Q1 2025 was Armistice Capital, an estimated $966K sold.
Based on aggregated 13F filings for Q1 2025.